OSSIO closed on US $22 million in equity financings that will support commercialization of the OSSIOfiber™ Bone Pin Family. Funds will support talent acquisition, commercialization, new product development and operational expansion. The company has raised $35MM to date; this round was led by venture capital firm OCV Partners and existing investors Ortho Vision and Secocha Ventures.
In January, OSSIO received its first FDA 510(k) market clearance for OSSIOfiber. The devices feature bio-integrative mineral/polymer material designed to provide stability and fixation that leaves no hardware behind. Preclinical studies have indicated that full integration into anatomy occurs within 18-24 months, leaving only native bone.
Product launch is slated for 2Q19 with an initial focus on forefoot conditions, though the platform will have broad application across orthopedics.
Sources: OSSIO; ORTHOWORLD Inc.
OSSIO closed on US $22 million in equity financings that will support commercialization of the OSSIOfiber™ Bone Pin Family. Funds will support talent acquisition, commercialization, new product development and operational expansion. The company has raised $35MM to date; this round was led by venture capital firm OCV Partners and existing...
OSSIO closed on US $22 million in equity financings that will support commercialization of the OSSIOfiber™ Bone Pin Family. Funds will support talent acquisition, commercialization, new product development and operational expansion. The company has raised $35MM to date; this round was led by venture capital firm OCV Partners and existing investors Ortho Vision and Secocha Ventures.
In January, OSSIO received its first FDA 510(k) market clearance for OSSIOfiber. The devices feature bio-integrative mineral/polymer material designed to provide stability and fixation that leaves no hardware behind. Preclinical studies have indicated that full integration into anatomy occurs within 18-24 months, leaving only native bone.
Product launch is slated for 2Q19 with an initial focus on forefoot conditions, though the platform will have broad application across orthopedics.
Sources: OSSIO; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





